Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax on Wednesday said that the postmarketing commitment study is anticipated to occur during 2025 and 2026 and cost ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

Novavax stock has plummeted from $290 a share in February 2021 to around $50 recently. The FDA finally appears poised to authorize the company's vaccine, however.